Insulin sensitizers

Farhad Zangeneh, Yogish C Kudva, Ananda Basu

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements. Insulin resistance is the most prominent feature common in both type 2 diabetes and its associated metabolic abnormalities. Until 1995, the only therapeutic interventions available in the United States were the insulin secretagogues sulfonylureas and insulin. With the introduction of metformin in the United States in the mid-1990s and the subsequent advent of thiazolidinediones, an opportunity exists to address and directly reverse, at least in part, the defects in insulin action seen in individuals with type 2 diabetes. Evidence shows that insulin sensitizers not only have beneficial effects on glycemic control but also have multiple effects on lipid metabolism and atherosclerotic vascular processes that could prove to be beneficial. We discuss safety issues of these agents, their potential use in preventing onset and progression of diabetes, and their use in other related metabolic conditions such as polycystic ovary syndrome.

Original languageEnglish (US)
Pages (from-to)471-479
Number of pages9
JournalMayo Clinic Proceedings
Volume78
Issue number4
StatePublished - Apr 1 2003

Fingerprint

Insulin
Type 2 Diabetes Mellitus
Thiazolidinediones
Polycystic Ovary Syndrome
Metformin
Lipid Metabolism
Blood Vessels
Insulin Resistance
Safety
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zangeneh, F., Kudva, Y. C., & Basu, A. (2003). Insulin sensitizers. Mayo Clinic Proceedings, 78(4), 471-479.

Insulin sensitizers. / Zangeneh, Farhad; Kudva, Yogish C; Basu, Ananda.

In: Mayo Clinic Proceedings, Vol. 78, No. 4, 01.04.2003, p. 471-479.

Research output: Contribution to journalArticle

Zangeneh, F, Kudva, YC & Basu, A 2003, 'Insulin sensitizers', Mayo Clinic Proceedings, vol. 78, no. 4, pp. 471-479.
Zangeneh F, Kudva YC, Basu A. Insulin sensitizers. Mayo Clinic Proceedings. 2003 Apr 1;78(4):471-479.
Zangeneh, Farhad ; Kudva, Yogish C ; Basu, Ananda. / Insulin sensitizers. In: Mayo Clinic Proceedings. 2003 ; Vol. 78, No. 4. pp. 471-479.
@article{a4ac367dcf7f406e855ac9b695f916a1,
title = "Insulin sensitizers",
abstract = "Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements. Insulin resistance is the most prominent feature common in both type 2 diabetes and its associated metabolic abnormalities. Until 1995, the only therapeutic interventions available in the United States were the insulin secretagogues sulfonylureas and insulin. With the introduction of metformin in the United States in the mid-1990s and the subsequent advent of thiazolidinediones, an opportunity exists to address and directly reverse, at least in part, the defects in insulin action seen in individuals with type 2 diabetes. Evidence shows that insulin sensitizers not only have beneficial effects on glycemic control but also have multiple effects on lipid metabolism and atherosclerotic vascular processes that could prove to be beneficial. We discuss safety issues of these agents, their potential use in preventing onset and progression of diabetes, and their use in other related metabolic conditions such as polycystic ovary syndrome.",
author = "Farhad Zangeneh and Kudva, {Yogish C} and Ananda Basu",
year = "2003",
month = "4",
day = "1",
language = "English (US)",
volume = "78",
pages = "471--479",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Insulin sensitizers

AU - Zangeneh, Farhad

AU - Kudva, Yogish C

AU - Basu, Ananda

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements. Insulin resistance is the most prominent feature common in both type 2 diabetes and its associated metabolic abnormalities. Until 1995, the only therapeutic interventions available in the United States were the insulin secretagogues sulfonylureas and insulin. With the introduction of metformin in the United States in the mid-1990s and the subsequent advent of thiazolidinediones, an opportunity exists to address and directly reverse, at least in part, the defects in insulin action seen in individuals with type 2 diabetes. Evidence shows that insulin sensitizers not only have beneficial effects on glycemic control but also have multiple effects on lipid metabolism and atherosclerotic vascular processes that could prove to be beneficial. We discuss safety issues of these agents, their potential use in preventing onset and progression of diabetes, and their use in other related metabolic conditions such as polycystic ovary syndrome.

AB - Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements. Insulin resistance is the most prominent feature common in both type 2 diabetes and its associated metabolic abnormalities. Until 1995, the only therapeutic interventions available in the United States were the insulin secretagogues sulfonylureas and insulin. With the introduction of metformin in the United States in the mid-1990s and the subsequent advent of thiazolidinediones, an opportunity exists to address and directly reverse, at least in part, the defects in insulin action seen in individuals with type 2 diabetes. Evidence shows that insulin sensitizers not only have beneficial effects on glycemic control but also have multiple effects on lipid metabolism and atherosclerotic vascular processes that could prove to be beneficial. We discuss safety issues of these agents, their potential use in preventing onset and progression of diabetes, and their use in other related metabolic conditions such as polycystic ovary syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0037382456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037382456&partnerID=8YFLogxK

M3 - Article

C2 - 12683699

AN - SCOPUS:0037382456

VL - 78

SP - 471

EP - 479

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -